BB BIOTECH AG
BB Biotech AG publishes its interim report
BB BIOTECH AG / Key word(s): Interim Report/Half Year Report Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules July 23, 2021 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2021, which covers the results of its business activities for the first six months of 2021. Based on the consolidated accounts of BB Biotech AG, net profit for the period ended June 30, 2021 amounted to CHF 349 mn (profit of CHF 422 mn in H1 2020). In the second quarter a profit of CHF 129 mn (profit of CHF 1’180 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio. BB Biotech AG’s interim report as at June 30, 2021 is available under report.bbbiotech.ch/Q221 or www.bbbiotech.com. For further information: Company profile
23-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Phone: | +41 52 624 08 45 |
E-mail: | info@bbbiotech.com |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
EQS News ID: | 1220897 |
End of Announcement | DGAP News Service |